Indications for: LUPRON DEPOT-PED
Central precocious puberty.
<1yr: not established. ≥1yrs: Individualize. Give by single IM inj once a month into the gluteal area, anterior thigh, or shoulder; rotate inj sites. ≤25kg: 7.5mg; 25–37.5kg: 11.25mg; >37.5kg: 15mg; if inadequate response with starting dose, may increase to next available higher dose. Also, dose may be adjusted with changes in body weight.
LUPRON DEPOT-PED Contraindications:
LUPRON DEPOT-PED Warnings/Precautions:
Must be administered by a healthcare professional. Initial transient rise in gonadotropins and sex steroids may result in increased signs/symptoms of puberty. Monitor LH and sex steroid levels at 1–2 months after treatment initiation, with dose changes, and as clinically indicated; for Depot 3-Month: monitor at months 2–3, month 6, and as clinically indicated; for Depot 6-Month: monitor at months 5–6, and as clinically indicated. Measure height and bone age velocity every 6–12 months. Monitor for pseudotumor cerebri or psychiatric symptoms. History of seizures/epilepsy, cerebrovascular disorders, CNS anomalies or tumors: risk of convulsions. Exclude pregnancy prior to initiation. Advise females of reproductive potential to use non-hormonal method of contraception during treatment. Nursing mothers.
LUPRON DEPOT-PED Classification:
LUPRON DEPOT-PED Interactions:
Caution with concomitant drugs that are associated with convulsions (eg, bupropion, SSRIs).
Transient exacerbation of symptoms, inj site reactions, pain, headache, emotional lability, acne/seborrhea, rash, vaginitis, vaginal discharge, syncope, GI upset, gynecomastia, weight increased, mood altered; also for Depot-PED 6-Month: psychiatric events, abdominal pain, diarrhea, hemorrhage, pyrexia, nausea/vomiting, ligament sprain, fracture, breast tenderness, insomnia, hyperhidrosis.
Half-life: ~3 hours.
Mean systemic clearance: 7.6 L/h.
Depot-PED kit—1 (prefilled dual-chamber syringe w. diluent, supplies)